[go: up one dir, main page]

MX2019004690A - Constructos de anticuerpos. - Google Patents

Constructos de anticuerpos.

Info

Publication number
MX2019004690A
MX2019004690A MX2019004690A MX2019004690A MX2019004690A MX 2019004690 A MX2019004690 A MX 2019004690A MX 2019004690 A MX2019004690 A MX 2019004690A MX 2019004690 A MX2019004690 A MX 2019004690A MX 2019004690 A MX2019004690 A MX 2019004690A
Authority
MX
Mexico
Prior art keywords
antibody constructs
constructs
presented
methods
same
Prior art date
Application number
MX2019004690A
Other languages
English (en)
Other versions
MX421186B (es
Inventor
Bailey Lucas
GLASER Bryan
Li Qufei
Green Roland
Original Assignee
Invenra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invenra Inc filed Critical Invenra Inc
Publication of MX2019004690A publication Critical patent/MX2019004690A/es
Publication of MX421186B publication Critical patent/MX421186B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se presentan constructos de anticuerpos multivalentes, composiciones farmacéuticas que comprenden los constructos y métodos de uso de los mismos.
MX2019004690A 2016-10-19 2017-10-18 Constructos de anticuerpos. MX421186B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662410054P 2016-10-19 2016-10-19
US201762549894P 2017-08-24 2017-08-24
US201762555498P 2017-09-07 2017-09-07
PCT/US2017/057268 WO2018075692A2 (en) 2016-10-19 2017-10-18 Antibody constructs

Publications (2)

Publication Number Publication Date
MX2019004690A true MX2019004690A (es) 2019-09-27
MX421186B MX421186B (es) 2025-02-10

Family

ID=60452719

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004690A MX421186B (es) 2016-10-19 2017-10-18 Constructos de anticuerpos.

Country Status (10)

Country Link
US (2) US20180118811A1 (es)
EP (1) EP3529269B1 (es)
JP (2) JP7261158B2 (es)
KR (3) KR20240000650A (es)
CN (3) CN118359704A (es)
AU (1) AU2017345454B2 (es)
CA (1) CA3041254A1 (es)
IL (1) IL266143A (es)
MX (1) MX421186B (es)
WO (1) WO2018075692A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201704283PA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
LT3468586T (lt) 2016-06-14 2024-12-10 Xencor, Inc. Bispecifiniai antikūnai prieš imuninės sistemos kontrolės taškų inhibitorius
KR20240000650A (ko) * 2016-10-19 2024-01-02 인벤라 인코포레이티드 항체 구조물
WO2019183406A1 (en) * 2018-03-21 2019-09-26 Invenra Inc. Multispecific antibody purification with ch1 resin
MX2020010267A (es) 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.
EP3781204A4 (en) * 2018-04-17 2022-03-30 Invenra, Inc. BINDING MOLECULES
IL316574A (en) 2018-04-18 2024-12-01 Exelixis Inc Structures of antibodies against ROR
CN114044827B (zh) * 2018-07-06 2024-06-07 北京天成新脉生物技术有限公司 低adcc/cdc功能性单抗及其制备方法与应用
US20220213225A1 (en) * 2018-07-30 2022-07-07 Invenra Inc. Multispecific treg binding molecules
CN112996809A (zh) * 2018-10-10 2021-06-18 酵活有限公司 结合4-1bb和肿瘤相关抗原的抗体构建体以及其用途
AU2019412561A1 (en) 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains
EP4077374A4 (en) * 2019-12-20 2023-12-27 Kisoji Biotechnology Inc. POLYPEPTIDES, PROTEIN COMPLEXES AND ASSOCIATED PRODUCTION PROCESS
CN115867309A (zh) * 2020-02-20 2023-03-28 温疗法公司 双特异性gd2和b7h2结合分子及使用方法
CN116867514A (zh) * 2020-12-10 2023-10-10 英温拉公司 用于异二聚化的正交突变
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
TW202506726A (zh) * 2023-04-07 2025-02-16 美商麥迪紐有限責任公司 雙特異性工程化抗體
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905551D0 (en) * 1989-03-10 1989-04-19 Unilever Plc Detergent compositions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2003263964C1 (en) 2002-07-31 2010-08-19 Seagen Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP3178492A1 (en) 2003-04-04 2017-06-14 Genentech, Inc. High concentration antibody and protein formulations
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
NZ547633A (en) 2003-11-06 2010-08-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
CA2621502A1 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
WO2009073445A2 (en) 2007-11-28 2009-06-11 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
EP3189831A1 (en) 2007-11-30 2017-07-12 AbbVie Biotechnology Ltd Protein formulations and methods of making same
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US8491880B2 (en) 2008-12-10 2013-07-23 Mersana Therapeutics, Inc. Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス， インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
SG176068A1 (en) 2009-06-03 2011-12-29 Immunogen Inc Conjugation methods
US9795674B2 (en) 2010-02-26 2017-10-24 Novo Nordisk A/S Stable antibody containing compositions
JP5919606B2 (ja) 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド 改良型高濃度抗ｔｎｆアルファ抗体液体製剤
HRP20180421T1 (hr) * 2010-11-17 2018-04-20 Chugai Seiyaku Kabushiki Kaisha Višestruko specifične molekule za vezanje na antigen koje imaju alternativnu funkciju u odnosu na funkciju faktora viii zgrušavanja krvi
SG193022A1 (en) 2011-03-10 2013-10-30 Eisai R&D Man Co Ltd Method for screening for compound capable of enhancing or inhibiting oatp1b1 transport activity, and method for determining expression level of oatp1b1
TWI603741B (zh) 2011-06-10 2017-11-01 梅爾莎納醫療公司 蛋白質-聚合物-藥物共軛體
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013033008A2 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
PT2794905T (pt) 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
HRP20191409T1 (hr) * 2012-04-20 2019-11-15 Merus Nv Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
KR102475777B1 (ko) 2012-05-15 2022-12-09 씨젠 인크. 자가-안정화 링커 접합체
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
AU2013334740A1 (en) 2012-10-25 2015-04-02 Medimmune, Llc Stable, low viscosity antibody formulation
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
US20160022829A1 (en) 2013-03-14 2016-01-28 Mersana Therapeutics, Inc. Tubulysin compounds and conjugates thereof
ES2726850T3 (es) 2013-10-11 2019-10-09 Mersana Therapeutics Inc Conjugados de proteína-polímero-fármaco
EA201690780A1 (ru) 2013-10-15 2016-08-31 Сиэтл Дженетикс, Инк. Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
KR102442906B1 (ko) 2013-12-19 2022-09-14 씨젠 인크. 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커
KR20240036143A (ko) 2014-02-17 2024-03-19 씨젠 인크. 친수성 항체-약물 컨쥬게이트
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
CN106132434A (zh) 2014-04-07 2016-11-16 西雅图基因公司 抗‑cd19抗体和抗体‑药物偶联物的稳定制剂
WO2015195925A1 (en) 2014-06-18 2015-12-23 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
TWI551060B (zh) * 2014-09-24 2016-09-21 衡宇科技股份有限公司 Ｂｃｈ解碼方法及其解碼器
CA2963615C (en) * 2014-12-05 2024-09-10 Merck Patent Gmbh ANTIBODIES WITH A DOMAIN EXCHANGE
WO2016180941A1 (en) 2015-05-13 2016-11-17 Sanofi Liquid compositions for anti-cd19 antibody-drug conjugates
SG10202009354SA (en) 2015-07-21 2020-11-27 Immunogen Inc Methods of preparing cytotoxic benzodiazepine derivatives
US20210299265A1 (en) 2016-02-05 2021-09-30 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
AU2017234163B2 (en) 2016-03-15 2023-01-19 Mersana Therapeutics, Inc. NaPi2b-targeted antibody-drug conjugates and methods of use thereof
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
EP3241531A1 (en) * 2016-05-04 2017-11-08 noonee AG Leg unit for a wearable sitting posture assisting device
KR20240000650A (ko) * 2016-10-19 2024-01-02 인벤라 인코포레이티드 항체 구조물
EP3781204A4 (en) * 2018-04-17 2022-03-30 Invenra, Inc. BINDING MOLECULES
CN112384243A (zh) * 2018-04-17 2021-02-19 英温拉公司 三价三特异性抗体构建体
IL316574A (en) * 2018-04-18 2024-12-01 Exelixis Inc Structures of antibodies against ROR
US20220213225A1 (en) * 2018-07-30 2022-07-07 Invenra Inc. Multispecific treg binding molecules
WO2021145946A1 (en) * 2020-01-13 2021-07-22 Invenra Inc. Multispecific treg binding molecules

Also Published As

Publication number Publication date
CN110177805B (zh) 2024-04-02
CN110177805A (zh) 2019-08-27
JP2022176374A (ja) 2022-11-25
CA3041254A1 (en) 2018-04-26
MX421186B (es) 2025-02-10
KR20190092380A (ko) 2019-08-07
CN118359705A (zh) 2024-07-19
JP7591015B2 (ja) 2024-11-27
JP7261158B2 (ja) 2023-04-19
NZ752832A (en) 2025-06-27
WO2018075692A3 (en) 2019-04-04
KR20250044934A (ko) 2025-04-01
AU2017345454A1 (en) 2019-05-30
EP3529269B1 (en) 2025-11-26
EP3529269A2 (en) 2019-08-28
JP2019534277A (ja) 2019-11-28
US20240043502A1 (en) 2024-02-08
KR102617264B1 (ko) 2023-12-29
AU2017345454B2 (en) 2024-10-31
CN118359704A (zh) 2024-07-19
US20180118811A1 (en) 2018-05-03
IL266143A (en) 2019-06-30
WO2018075692A2 (en) 2018-04-26
KR20240000650A (ko) 2024-01-02

Similar Documents

Publication Publication Date Title
MX2019004690A (es) Constructos de anticuerpos.
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
CL2020000281A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39
CY1125241T1 (el) Υποδορια σκευασματα αντισωματων anti-cd38 και οι χρησεις τους
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
DOP2019000165A (es) Anticuerpos anti-ox40 y sus usos
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
BR112019012342A2 (pt) anticorpos il-11
BR112019012343A2 (pt) anticorpos il-11ra
CO2018012699A2 (es) Anticuerpos anti-cd40 y sus usos
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MX2018008369A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.